Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia

Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining therapeutically effective drug levels.Methods: A mul...

Description complète

Détails bibliographiques

Auteurs principaux:	Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Caroline Lohrisch, Colin J. D. Ross, Bruce C. Carleton
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2023-09-01
Collection:	Frontiers in Pharmacology
Sujets:	adverse drug reactions clinical implementation DPYD fluoropyrimidine toxicity pharmacogenetics
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1257745/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!